Stock Track | Becton Dickinson Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Stock Track11-08

Becton Dickinson (BD) reported strong financial results for the fourth quarter and full fiscal year 2024, driven by strategic acquisitions and portfolio shifts into higher-growth areas like biologics, artificial intelligence (AI), and automation.

Key highlights for Q4 FY2024:

Revenue increased 6.9% year-over-year to $5.44 billion, beating analysts' estimates of $5.38 billion.
Adjusted diluted earnings per share (EPS) grew 11.4% to $3.81, exceeding expectations of $3.77.
BD Medical segment sales rose 11.1% to $2.84 billion, led by strong growth in Medication Management Solutions.
BD Life Sciences segment revenue increased slightly by 0.7% to $1.34 billion.
BD Interventional segment sales increased 4.7% to $1.26 billion.

For the full fiscal year 2024:

Revenue grew 4.2% to $20.18 billion.
Adjusted EPS increased 7.6% to $13.14.
Cash from operating activities rose 28.5% to $3.8 billion.
Free cash flow grew 47.4% to $3.1 billion.

BD's acquisition of Edwards Lifesciences' Critical Care Product Group, renamed as BD Advanced Patient Monitoring, and its focus on high-growth areas like biologics, AI, and automation have been pivotal in driving its performance.

Looking ahead to fiscal 2025, BD forecasts revenue growth of 8.9% to 9.4%, adjusted currency-neutral growth of 8.8% to 9.3%, and adjusted EPS growth of about 10% at the midpoint, indicating confidence in continued value creation for shareholders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183264946?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 03:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183264946","market":"hk","top_or_hot":-1,"title":"Stock Track | Becton Dickinson Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results","media":"Stock Track","content":"<p>Becton Dickinson (BD) reported strong financial results for the fourth quarter and full fiscal year 2024, driven by strategic acquisitions and portfolio shifts into higher-growth areas like biologics, artificial intelligence (AI), and automation.</p>\n\n<p>Key highlights for Q4 FY2024:</p>\n<ul>\n<li>Revenue increased 6.9% year-over-year to $5.44 billion, beating analysts' estimates of $5.38 billion.</li>\n<li>Adjusted diluted earnings per share (EPS) grew 11.4% to $3.81, exceeding expectations of $3.77.</li>\n<li>BD Medical segment sales rose 11.1% to $2.84 billion, led by strong growth in Medication Management Solutions.</li>\n<li>BD Life Sciences segment revenue increased slightly by 0.7% to $1.34 billion.</li>\n<li>BD Interventional segment sales increased 4.7% to $1.26 billion.</li>\n</ul>\n\n<p>For the full fiscal year 2024:</p>\n<ul>\n<li>Revenue grew 4.2% to $20.18 billion.</li>\n<li>Adjusted EPS increased 7.6% to $13.14.</li>\n<li>Cash from operating activities rose 28.5% to $3.8 billion.</li>\n<li>Free cash flow grew 47.4% to $3.1 billion.</li>\n</ul>\n\n<p>BD's acquisition of Edwards Lifesciences' Critical Care Product Group, renamed as BD Advanced Patient Monitoring, and its focus on high-growth areas like biologics, AI, and automation have been pivotal in driving its performance.</p>\n\n<p>Looking ahead to fiscal 2025, BD forecasts revenue growth of 8.9% to 9.4%, adjusted currency-neutral growth of 8.8% to 9.3%, and adjusted EPS growth of about 10% at the midpoint, indicating confidence in continued value creation for shareholders.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Becton Dickinson Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Becton Dickinson Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-08 03:16 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Becton Dickinson (BD) reported strong financial results for the fourth quarter and full fiscal year 2024, driven by strategic acquisitions and portfolio shifts into higher-growth areas like biologics,...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BDX","symbol_name":"碧迪医疗","start_time":0,"source_url":"","article_id":"1183264946","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183264946","pubTimestamp":1731006978,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Becton Dickinson  reported strong financial results for the fourth quarter and full fiscal year 2024, driven by strategic acquisitions and portfolio shifts into higher-growth areas like biologics, artificial intelligence , and automation.Revenue increased 6.9% year-over-year to $5.44 billion, beating analysts' estimates of $5.38 billion.Adjusted diluted earnings per share  grew 11.4% to $3.81, exceeding expectations of $3.77.BD Medical segment sales rose 11.1% to $2.84 billion, led by strong gro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BDX":"碧迪医疗"},"translate_title":"股票追踪Becton Dickinson报告2024财年第四季度和全年财务业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDX":1},"content_text":"Becton Dickinson (BD) reported strong financial results for the fourth quarter and full fiscal year 2024, driven by strategic acquisitions and portfolio shifts into higher-growth areas like biologics, artificial intelligence (AI), and automation.\nKey highlights for Q4 FY2024:\n\nRevenue increased 6.9% year-over-year to $5.44 billion, beating analysts' estimates of $5.38 billion.\nAdjusted diluted earnings per share (EPS) grew 11.4% to $3.81, exceeding expectations of $3.77.\nBD Medical segment sales rose 11.1% to $2.84 billion, led by strong growth in Medication Management Solutions.\nBD Life Sciences segment revenue increased slightly by 0.7% to $1.34 billion.\nBD Interventional segment sales increased 4.7% to $1.26 billion.\n\nFor the full fiscal year 2024:\n\nRevenue grew 4.2% to $20.18 billion.\nAdjusted EPS increased 7.6% to $13.14.\nCash from operating activities rose 28.5% to $3.8 billion.\nFree cash flow grew 47.4% to $3.1 billion.\n\nBD's acquisition of Edwards Lifesciences' Critical Care Product Group, renamed as BD Advanced Patient Monitoring, and its focus on high-growth areas like biologics, AI, and automation have been pivotal in driving its performance.\nLooking ahead to fiscal 2025, BD forecasts revenue growth of 8.9% to 9.4%, adjusted currency-neutral growth of 8.8% to 9.3%, and adjusted EPS growth of about 10% at the midpoint, indicating confidence in continued value creation for shareholders.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183264946"}